Crohn’s Disease Market

Market Overview

Crohn's Disease Market size was valued at USD 11.1 Billion in 2022 and is projected to grow from USD 11.5 Billion in 2023 to USD 14.3 Billion by 2030, growing at a compound annual growth rate (CAGR ) by 3.70% over the forecast period (2023 - 2030). One of the major market drivers fueling the expansion of the market is the rising prevalence of Crohn's disease due to changes in people's lifestyles. Governments around the world have made major investments in creating medical infrastructure that will provide better facilities for the treatment of disease and help the economy to thrive.

Market Dynamics

The Crohn's disease market dynamics are influenced by various factors:

  • Increasing prevalence: The rising incidence and prevalence of Crohn's disease worldwide contribute to the growth of the market, creating a greater demand for effective therapies.
  • Advancements in treatment options: The development of novel drugs and therapies, including biologics and targeted therapies, has expanded the treatment landscape for Crohn's disease, offering patients more options for managing their condition.
  • Healthcare expenditure: The high cost of Crohn's disease management, including medications, hospitalization, and surgery, drives the market growth, as healthcare expenditure continues to increase.
  • Research and development: Ongoing research efforts focusing on understanding the disease mechanisms and exploring new therapeutic targets contribute to the evolution of the market.
  • Patient-centric approach: With a growing emphasis on patient-centered care, there is a greater focus on improving the quality of life for individuals with Crohn's disease, leading to the development of innovative therapies and support services.

Market Drivers

The Crohn's disease market is driven by several factors. Firstly, the increasing prevalence of the disease worldwide fuels the demand for effective treatments. Secondly, advancements in treatment options, such as biologics and targeted therapies, offer new avenues for managing the disease. Thirdly, the growing healthcare expenditure allocated to Crohn's disease management drives market growth. Additionally, ongoing research and development efforts focused on understanding the disease's mechanisms and developing innovative therapies contribute to market expansion. Lastly, a patient-centric approach that aims to improve the quality of life for individuals with Crohn's disease further drives the development of new treatments and support services.

Market Restraints

The Crohn's disease market faces certain restraints. Firstly, the etiology of Crohn's disease is not fully understood, making it challenging to develop targeted therapies. Secondly, the high cost of treatment, including biologics and surgical interventions, can limit access to care for some patients. Thirdly, the potential side effects and risks associated with existing treatments pose concerns for patients and may impact treatment adherence. Additionally, the unpredictable nature of the disease and the occurrence of flare-ups make it difficult to achieve long-term remission. Lastly, regulatory hurdles and the lengthy and costly drug approval process can impede the introduction of new therapies into the market.

Market Trends

Rising prevalence of inflammatory bowel disorders (IBD) to propel market growth

Inflammation and irritation of the digestive tract are symptoms of Crohn's disease, a type of inflammatory bowel disease (IBD). Although this condition can affect any section of the gastrointestinal tract, including the mouth and stomach, it most commonly affects the small intestine and colon. The Crohn's disease market is expected to grow rapidly due to factors such as the increase in inflammatory bowel disorders (IBD) and the number of Crohn's disease patients. For example, a disease-death model based on the available data was built to predict the future prevalence of IBD in Asia, and Iran in particular, from 2017 to 2035, according to a paper published by the Journal BMC Gastroenterology in May 2021. The study predicts a 2.5-fold increase in prevalence for Iran with 69,000 cases in 2035 compared to 2020, a 2.3-fold increase for North Africa and the Middle East with 220,000 cases, a fourfold increase in prevalence for India with 2.2 million cases, a 1.5-fold increase for the East Asia region with 4.5 million cases, and a 1.6-fold increase for the high-income regions of Asia-Pacific and Southeast Asia with 183 and 199,000 cases, respectively. Thus, this factor is driving the market CAGR for Crohn's disease.

However, another important element driving the growth of the Crohn's disease market is the creation of innovative and powerful treatment options to treat the symptoms of the disease. For example, at the Crohn's Disease and Colitis Congress held in January 2018, researchers from Washington University of Medicine presented a study that produced an antibiotic that demonstrated a four times better response. to inflammation of the intestine in patients with Crohn's disease compared to currently available therapies. Thus, this aspect is predicted to accelerate the Crohn's disease market revenue globally.

Market Segment:


Crohn's disease market segmentation, based on type, includes ileocolitis, ileitis, granulomatous colitis, gastroduodenal Crohn's disease, jejunoileitis, and perianal Crohn's disease. Ileocolitis segment held majority share in 2022 in Crohn's disease market data. The most common form of Crohn's disease is ileocolitis. The last segment of the small intestine and part of the large intestine then become inflamed. It belongs to a class of diseases called inflammatory bowel disease (IBD) and is a lifelong chronic condition that is currently incurable.


Market segmentation for the treatment of Crohn's disease includes both non-surgical and surgical options. In terms of market growth for Crohn's disease, the surgical sector took the lead in 2022 and is predicted to increase at the quickest rate from 2022 to 2030. Non-surgical therapies are the most often used since they are less expensive and intrusive. One of the most often used non-surgical therapies is the family of medications known as immune system suppressors and TNF inhibitors. The market for these kinds of treatments is probably going to expand significantly further with considerable breakthrough in drug technology.


Market data for Crohn's disease, based on the end user, includes hospitals, clinics and research institutes. Hospitals and clinics segment dominated Crohn's disease market revenue in 2022 and is expected to be the fastest growing segment during the forecast period, 2022-2030, due to factors such as a large patient population and the existence of units specifically designed to diagnose and treat inflammatory bowel disease A growing number of people with Crohn's disease and knowledge of the treatment of the disease are other factors that contribute to the expansion of this category.

Post COVID Impact

The post-COVID-19 era has left a lasting impact on various sectors, including the healthcare industry. The Crohn's Disease market, which focuses on the treatment and management of this chronic inflammatory bowel disease, has experienced significant changes.

Firstly, there has been a greater emphasis on telemedicine and remote healthcare services, allowing patients with Crohn's Disease to consult their physicians virtually, reducing the need for in-person visits. This has improved accessibility to healthcare for patients in remote areas and minimized the risk of exposure to infections.

Additionally, the pandemic has prompted increased research and development efforts in the field of Crohn's Disease. The urgent need for effective treatments and therapies for COVID-19 has accelerated advancements in related fields, including immunology and inflammation, which are also crucial in understanding and managing Crohn's Disease.

Furthermore, the pandemic has highlighted the importance of mental health support for individuals with chronic illnesses. The isolation and anxiety experienced during the COVID-19 lockdowns have shed light on the need for comprehensive care that addresses both physical and mental well-being of Crohn's Disease patients.

Overall, the post-COVID-19 era has driven changes in the Crohn's Disease market, promoting digital healthcare solutions, advancing research, and underscoring the significance of holistic patient care.

Geographical Regional

By region, the study provides information on the Crohn's disease market in North America, Europe, Asia-Pacific and the rest of the world. The North America Crohn's disease market was worth USD 5.1 billion in 2022 with a share of approximately 45.80% and is expected to exhibit significant growth in CAGR during the study period owing to the increase Crohn's disease rates and increased awareness of various therapies. According to CDC data, approximately 3 million people in the United States alone have been diagnosed with Crohn's disease. A significant portion of the patient population is from Canada. Better medical literacy and more developed healthcare infrastructure are factors driving the expansion of the market in this region.

The European Crohn's disease market accounts for the second largest market share as more and more patients are diagnosed with this disease and seek out available treatments. The main causes of the disease are currently thought to be dietary habits and sedentary lifestyles. However, good medical research, availability of better drugs and treatments are helping to expand the market in this region. Additionally, the UK Crohn's disease market held the largest market share, and the German Crohn's disease market was the fastest growing market in the region.

Asia-Pacific Crohn's Disease Market is anticipated to grow at the fastest CAGR from 2022 to 2030 owing to growing patient and family awareness of available therapies, along with expanding economies of countries like China and the United States. 'India. By 2035, the prevalence of this disease is predicted to have quadrupled in this region. In order to treat the growing number of patients, it will be beneficial to invest in strengthening the health infrastructure. Additionally, the Chinese Crohn's disease market held the largest market share, and the Indian Crohn's disease market was the fastest growing market in the region.

Competitive Insights

The major market players are spending lots of money on R&D to increase their product lines which will further contribute to the growth of the Crohn's disease market. Market players are also taking a series of strategic initiatives to increase their global footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments and collaboration with other organizations. Competitors in the Crohn's Disease industry must offer profitable items to grow and survive in an increasingly competitive and rising market environment.

One of the major business strategies adopted by the manufacturers in the global Crohn's disease industry to benefit the customers and expand the market sector is to manufacture locally to reduce the operation cost. In recent years, the Crohn's disease industry has provided medicine with some of the most significant benefits. Major Crohn's Disease market players such as Johnson & Johnson Services Inc, Pfizer Inc, Allergan, AbbVie Inc, Bayer AG, Amgen Inc and Takeda Pharmaceutical Company Limited.

Founded in 2013, American biopharmaceutical company AbbVie is publicly traded. It all started as a spin-off from Abbott Laboratories. A biopharmaceutical company, founded by AbbVie, combines the focus and culture of a biotech with the stability, global reach, resources and commercial capabilities of a pharmaceutical company. Its goal is to find and distribute cutting-edge medicines and technologies that will improve people's lives today, treat medical problems of the future, and address critical health crises. In June 2022, AbbVie Inc., a biopharmaceutical company, announced that the FDA had cleared SKYRIZI (risankizumab-rzaa) (CD).

Also, an international pharmaceutical company with some American and British heritage, The Takeda Pharmaceutical Company Limited is based in Japan. It is among the top 20 pharmaceutical companies in the world by revenue and is the largest pharmaceutical company in Asia (top 10 following its merger with Shire). The company has approximately 49,578 people worldwide, and its sales for fiscal year 2018 were $19.299 billion. Oncology, rare diseases, neurosciences, gastrointestinal, plasma-derived drugs and vaccines are the company's main focus areas. Its head office is in Nihonbashi, Chuo, Tokyo, while its head office is in Chuo-ku, Osaka. In April 2022, to expand an existing agreement to cover the discovery and creation of entirely new therapies for fibrostenotic inflammatory bowel disease, including Crohn's disease, Engitix and Takeda worked together.

Key Companies in the Crohn’s disease market includes

  • Johnson & Johnson Services Inc
  • Pfizer Inc
  • Allergan
  • AbbVie Inc
  • Bayer AG
  • Amgen Inc
  • Takeda Pharmaceutical Company Limited

Industry Developments

April 2022: The Crohn's and Colitis Foundation provided project funding to Microbiotica as a part of its inflammatory bowel disease ventures programme for the creation of inflammatory bowel disease treatments.

March 2022: Foralumab (TZLS-401), a monoclonal antibody (mAb), was being tested in a Phase Ib clinical trial by the biotechnology company Tiziana Life Sciences on people with mild-to-moderate Crohn's disease (CD).

May 2021: The US Food and Drug Administration has given the green light to Bristol Myers Squibb's Zeposia® (ozanimod), an oral medication for adults with moderately to severely active ulcerative colitis.

Market Segmentation:


  • Ileocolitis
  • Ileitis
  • Granulomatous colitis
  • Gastroduodenal Crohn’s Disease
  • Jejunoileitis
  • Perianal Crohn’s Disease


  • Non-Surgical
  • Surgical


  • Hospitals and Clinics
  • Research Institutes


  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East
    • Africa

Latin America

Why Choose Us

Inclusion of Pre-clinical Molecules

Other than an extensive coverage of clinical and commercial drugs, our reports also provide details about pre-clinical molecules!


One of our marquee services We profile relevant start-up companies in the market.


Get access to reliable data our insights and analyses are backed by Key Opinion Leaders in the field.

Specialized in Healthcare

Our team comprises of industry specialists and research experts from life sciences area holding degree in Medicine, Doctor of Pharmacy, M.Sc. in Pharmacy, Pharma MBAs, and Biotechnology.